Pacira Pharmaceuticals (NASDAQ:PCRX) received a $49.00 target price from equities researchers at Piper Jaffray Companies in a report issued on Tuesday. The brokerage currently has a “buy” rating on the stock. Piper Jaffray Companies’ target price points to a potential upside of 35.73% from the company’s current price.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $52.00 target price on shares of Pacira Pharmaceuticals in a research report on Thursday, November 9th. Jefferies Group dropped their target price on Pacira Pharmaceuticals to $52.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. Needham & Company LLC dropped their target price on Pacira Pharmaceuticals from $55.00 to $52.00 and set a “buy” rating on the stock in a research report on Thursday, October 19th. Wedbush reiterated a “buy” rating and issued a $80.00 target price on shares of Pacira Pharmaceuticals in a research report on Monday, November 20th. Finally, BidaskClub upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $48.47.

Shares of Pacira Pharmaceuticals (PCRX) opened at $36.10 on Tuesday. The company has a market capitalization of $1,474.72, a P/E ratio of -27.56 and a beta of 1.88. Pacira Pharmaceuticals has a 52-week low of $29.81 and a 52-week high of $58.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24.

In other Pacira Pharmaceuticals news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total value of $1,160,888.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Kristen Marie Williams sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the chief accounting officer now owns 23,455 shares in the company, valued at approximately $938,200. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,075 shares of company stock worth $1,610,690. Insiders own 6.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC boosted its position in Pacira Pharmaceuticals by 121.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after purchasing an additional 1,752 shares in the last quarter. QS Investors LLC purchased a new position in shares of Pacira Pharmaceuticals during the 2nd quarter valued at approximately $157,000. Ameritas Investment Partners Inc. lifted its position in shares of Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after buying an additional 302 shares in the last quarter. Spectrum Management Group Inc. purchased a new position in shares of Pacira Pharmaceuticals during the 3rd quarter valued at approximately $166,000. Finally, First Republic Investment Management Inc. purchased a new position in shares of Pacira Pharmaceuticals during the 4th quarter valued at approximately $201,000.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/15/pacira-pharmaceuticals-pcrx-given-a-49-00-price-target-at-piper-jaffray-companies.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.